Erosive osteoarthritis of the hand: clinical experience with anakinra
Immuno-Rheumatology, Lapeyronie University Hospital, Montpellier, France
Correspondence to:
L Bacconier, Immuno-Rheumatology, Lapeyronie University Hospital, Montpellier, France; ludovicbacconnier@yahoo.fr
Accepted 6 September 2008
| The first 150 words of the full text of this article appear below. |
Erosive osteoarthritis (EOA) is an important subtype of OA, characterised by an aggressive clinical course in perimenopausal women.1 Pain, swelling, redness, warmth and limited function of the digital joints are commonly found in most patients. Erosions (sharp marginal defects, central "crumbling" erosion, "gull-wing" deformity) are an essential hallmark for diagnosis. EOA eventually leads to joint deformity and ankylosis and is an important cause of disability, usually compared to the handicap caused by rheumatoid arthritis.
There are currently no guidelines on the best therapeutic approach in EOA, and treatments usually recommended for patients who do not have EOA (paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular injection of corticosteroids, chondroitin sulfate) or physiotherapy are frequently disappointing.
Recent research has highlighted the role of interleukin(IL) 1 in disease progression. Proinflammatory cytokines such as IL1β and, to a lesser extent, tumour necrosis factor
, play a key role in the destruction of the cartilage matrix
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
